Fysiologiske virkninger af kontinuerligt negativt eksternt tryk for akut hypoxæmisk respirationssvigt
This study is being conducted to evaluate if wearing a non-invasive breathing support device over the chest/abdomen improves markers of breathing in patients with lung injury requiring high-flow oxygen. The breathing support device consists of a plastic shell that sits over the chest and abdomen and connects to a vacuum that helps the chest expand with breathing. This breathing support is known as continuous negative external pressure (CNEP). Study findings will help determine if this breathing support device might be useful for patients with acute hypoxemic respiratory failure (AHRF).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study is a prospective randomized cross-over trial. Eligible, consenting participants will undergo 4 strategies of respiratory support: high-flow nasal cannula (HFNC) only, HFNC + continuous negative external pressure (CNEP) of 10 cmH2O, HFNC + CNEP of 20 cmH2O, HFNC + CNEP of 30 cmH2O. Throughout the study period, HFNC will be managed at a constant flow rate with fraction of inspired oxygen (FiO2) titrated to achieve goal oxygen saturation (SpO2) of 90-97%, measured via continuous pulse-oximetry. Each of the 4 strategies will be performed for 45 minutes per strategy, interspersed with a 15-minute washout period of HFNC only. Participants will be randomized to the sequence of strategies for respiratory support.
A summary of the sequence of trial procedures is as follows:
- Perform baseline measures.
- Wait 5-10 minutes for recovery.
- Initiate first random treatment assignment for up to 45 minutes.
- HFNC-only washout for 15 minutes
- Initiate second random treatment assignment for up to 45 minutes.
- HFNC-only washout for 15 minutes
- Initiate third random treatment assignment for up to 45 minutes.
- HFNC-only washout for 15 minutes
- Initiate fourth random treatment assignment for up to 45 minutes.
- Return to usual care (HFNC only)
If a participant does not tolerate a given level of CNEP, the patient will be returned to HFNC for 5 minutes and then given the option to attempt that CNEP level again. If the patient declines reattempt or does not tolerate that CNEP level on reattempt, the HFNC-only washout will be instituted for 15 minutes before proceeding to the next protocol step.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Jeremy Beitler, MD, MPH
- Telefonnummer: 646-929-7870
- E-mail: jeremy.beitler@nyulangone.org
Studiesteder
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11220
- Rekruttering
- NYU Langone Health - Brooklyn Hospital
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Bellevue Hospital
-
New York, New York, Forenede Stater, 10032
- Afsluttet
- Columbia University Irving Medical Center
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- NYU Langone Health - NYU Tisch-Kimmel Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Acute hypoxemic respiratory failure
- Non-cardiogenic airspace opacities on chest radiograph or computed tomography (CT) scan
- High-flow nasal cannula (flow ≥ 30 LPM) initiated within last 96 hours (4 days)
- FiO2 ≥ 40%
- SpO2 ≥ 92%
Exclusion Criteria:
-
Do-not-intubate order
-
Anatomical factor predisposing to poor fit of cuirass (e.g. severe kyphosis or scoliosis)
-
Use of cuirass precluded, e.g. due to:
- Clinically prescribed prone positioning
- Tense ascites
- Severe abdominal pain
- Abdominal wound or surgery, symptomatic abdominal aortic aneurysm, or other unstable or high-risk intra-abdominal pathology
- Pregnancy
- Agitated delirium
- Body weight > 180 kg
- Burned skin or draining wounds under the planed cuirass area
- Indwelling tube/drain entry sites within the planned cuirass seat path
-
Prior intubation during hospital stay
-
Cardiogenic pulmonary edema
-
Exacerbation of asthma or COPD
-
Chronic lung disease, including:
- Interstitial lung disease
- Cystic fibrosis
- Lung mass, lung cancer, or metastasis to the lung
- Lung transplant recipient
- Any disease that requires home oxygen
-
Glasgow coma score < 15
-
Chest tube, pneumothorax, or pneumomediastinum
-
Hemodynamic instability, defined as any of:
- Heart rate < 50 beats/minute
- Mean arterial pressure < 55 mmHg
- Norepinephrine-equivalent vasopressor requirement > 0.1mcg/kg/min
-
Implantable electrical device (e.g. pacemaker, defibrillator, neurostimulator)
-
Unreliable pulse-oximetry tracing
-
Imminent intubation
-
Anticipated lack of patient availability to complete study procedures (e.g. due to planned clinical procedure such as CT scan or dialysis during potential time of study)
-
Attending physician refusal
-
Lack of capacity for direct consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Kun HFNC
|
HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97% |
|
Eksperimentel: HFNC + CNEP10
|
HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97% |
|
Eksperimentel: HFNC + CNEP20
|
HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97% |
|
Eksperimentel: HFNC + CNEP30
|
HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97% |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in SpO2/FiO2
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in SpO2/FiO2 within each participant as measured at baseline and at the end of each treatment assignment period. The average SpO2/FiO2 over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in Respiratory Rate
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Respiratory Rate within each participant as measured at baseline and at the end of each treatment assignment period. The average Respiratory Rate over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in ROX Index
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in ROX index within each participant as measured at baseline and at the end of each treatment assignment period. ROX index is calculated as SpO2/FiO2 divided by the Respiratory Rate. The average ROX index over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Transcutaneous Carbon Dioxide (CO2)
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Transcutaneous Carbon Dioxide within each participant as measured at baseline and at the end of each treatment assignment period. The average Transcutaneous Carbon Dioxide over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Heart Rate
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Heart Rate within each participant as measured at baseline and at the end of each treatment assignment period. The average Heart Rate over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Blood Pressure
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Blood Pressure within each participant as measured at baseline and at the end of each treatment assignment period. The average Blood Pressure over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Breathing Discomfort
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Breathing Discomfort within each participant as measured at baseline and at the end of each treatment assignment period. Breathing Discomfort will be measured with component A1 of the Multidimensional Dyspnea Profile. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Lightheadedness
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Lightheadedness within each participant as measured at baseline and at the end of each treatment assignment period. Lightheadedness will be measured with an ordinal scale ranging from 0 to 10. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Nausea
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Nausea within each participant as measured at baseline and at the end of each treatment assignment period. Nausea will be measured with an ordinal scale ranging from 0 to 10. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Skin Discomfort
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in patient-reported Skin Discomfort as measured at baseline and at the end of each treatment assignment period. Skin Discomfort will be measured with an ordinal scale ranging from 0 to 10. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Skin Erythema
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Skin Erythema within each participant as measured at baseline and at the end of each treatment assignment period. Skin erythema will be measured by investigator visual assessment using a five-point scale. |
At the end of each treatment period, up to 45 minutes
|
|
Tolerance of intervention period
Tidsramme: For the duration of each treatment period, up to 45 minutes
|
Patient able to complete the entire treatment period of intervention without early discontinuation for intolerance |
For the duration of each treatment period, up to 45 minutes
|
|
Proportion of time within 3 cm H2O of target CNEP level
Tidsramme: For the duration of each treatment period, up to 45 minutes
|
Ability to reach and maintain the target CNEP level, defined as CNEP within ± 3 cm H2O of the prescribed value |
For the duration of each treatment period, up to 45 minutes
|
|
Proportion of time within 5 cm H2O of target CNEP level
Tidsramme: For the duration of each treatment period, up to 45 minutes
|
Ability to reach and maintain the target CNEP level, defined as CNEP within ± 5 cm H2O of the prescribed value |
For the duration of each treatment period, up to 45 minutes
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in other components of the Multidimensional Dyspnea Profile
Tidsramme: At end of study
|
The change in other components of the Multidimensional Dyspnea Profile within each participant as measured at baseline and at the end of the study. At end of study, participants will be instructed to consider their breathing on average during CNEP to obtain the post-baseline measure. |
At end of study
|
|
Change from baseline in Tidal Volume
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Tidal Volume within each participant as measured at baseline and at the end of each treatment assignment period, estimated from lung electrical impedance tomography. The average Tidal Volume over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in End-Expiratory Lung Volume
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in End-Expiratory Lung Volume within each participant as estimated from end-expiratory lung impedance measured at baseline and at the end of each treatment assignment period. The average End-Expiratory Lung Impedance over the last five minutes of the treatment period will be used to derive change in end-expiratory lung volume. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Minute Ventilation
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Minute Ventilation within each participant as measured at baseline and at the end of each treatment assignment period, estimated from lung electrical impedance tomography. The average Minute Ventilation over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
|
Change from baseline in Anteroposterior Ventilation Ratio
Tidsramme: At the end of each treatment period, up to 45 minutes
|
The change in Anteroposterior Ventilation Ratio within each participant as measured at baseline and at the end of each treatment assignment period, estimated from lung electrical impedance tomography. The average Anteroposterior Ventilation Ratio over the last five minutes of the treatment period will be used. |
At the end of each treatment period, up to 45 minutes
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Jeremy Beitler, MD, MPH, Columbia University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 26-00257
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .